MANNKIND CORP Proceeds from Sale and Maturity of Held-to-maturity Securities
MANNKIND CORP (MNKD) reported Proceeds from Sale and Maturity of Held-to-maturity Securities of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities · last filed 2026-02-26
- MANNKIND CORP proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2024-09-30 was $46.50M, a 97.67% increase year-over-year.
- MANNKIND CORP proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2024-06-30 was $66.84M, a 42.27% increase year-over-year.
- MANNKIND CORP proceeds from sale and maturity of held-to-maturity securities for fiscal 2024 was $135.32M, a 13.55% increase from fiscal 2023.
- MANNKIND CORP proceeds from sale and maturity of held-to-maturity securities for fiscal 2023 was $119.17M, a 11.02% increase from fiscal 2022.
- MANNKIND CORP proceeds from sale and maturity of held-to-maturity securities for fiscal 2022 was $107.34M, a 81.75% increase from fiscal 2021.
- MANNKIND CORP proceeds from sale and maturity of held-to-maturity securities for fiscal 2021 was $59.06M.
| Period end | Proceeds from Sale and Maturity of Held-to-maturity Securities 3 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 6 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 9 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $46.50M derived: sum of 3 quarters · filed 2026-02-26 | $113.34M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.50M derived: sum of 2 quarters · filed 2026-02-26 | $113.34M derived: sum of 3 quarters · filed 2026-02-26 | $135.32M 10-K · filed 2026-02-26 |
| 2024-09-30 | $46.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $113.34M derived: sum of 2 quarters · filed 2025-11-05 | $135.32M 10-Q · filed 2025-11-05 | $161.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $66.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $88.81M 10-Q · filed 2025-08-06 | $115.37M derived: sum of 3 quarters · filed 2026-02-26 | $138.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $21.97M 10-Q · filed 2025-05-08 | $48.53M derived: sum of 2 quarters · filed 2026-02-26 | $72.06M derived: sum of 3 quarters · filed 2026-02-26 | $119.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $26.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $50.08M derived: sum of 2 quarters · filed 2026-02-26 | $97.06M derived: sum of 3 quarters · filed 2026-02-26 | $119.17M 10-K · filed 2026-02-26 |
| 2023-09-30 | $23.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $70.50M derived: sum of 2 quarters · filed 2024-11-07 | $92.61M 10-Q · filed 2024-11-07 | $117.36M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $46.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $69.08M 10-Q · filed 2024-08-07 | $93.84M derived: sum of 3 quarters · filed 2025-02-26 | $123.12M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $22.10M 10-Q · filed 2024-05-08 | $46.86M derived: sum of 2 quarters · filed 2025-02-26 | $76.14M derived: sum of 3 quarters · filed 2025-02-26 | $102.91M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $24.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $54.03M derived: sum of 2 quarters · filed 2025-02-26 | $80.80M derived: sum of 3 quarters · filed 2025-02-26 | $107.34M 10-K · filed 2025-02-26 |
| 2022-09-30 | $29.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $56.05M derived: sum of 2 quarters · filed 2023-11-07 | $82.58M 10-Q · filed 2023-11-07 | $35.92M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $26.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $53.31M 10-Q · filed 2023-08-07 | $6.64M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2022-03-31 | $26.54M 10-Q · filed 2023-05-09 | -$20.13M derived: sum of 2 quarters · filed 2024-02-27 | ||
| 2021-12-31 | -$46.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $59.06M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $105.72M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |